Search research articles
Contact Us
Filters
Showing results (921-930 of 948) with videos related to
Page
of 95
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 2017
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2019
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
Wen-Zhao Zhong, Ke-Neng Chen, Chun Chen, et al.
Cell Reports. Medicine
|
January 19, 2023
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study
Han-Min Wang, Chan-Yuan Zhang, Kai-Cheng Peng, et al.
Science Bulletin
|
January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial
Si-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
Signal Transduction and Targeted Therapy
|
December 6, 2023
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Si-Yang Liu, Song Dong, Xue-Ning Yang, et al.
Science Advances
|
April 21, 2023
Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease
Lan-Ting Zhou, Dan Liu, Hui-Cong Kang, et al.
Signal Transduction and Targeted Therapy
|
February 23, 2023
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, et al.
Cancer Discovery
|
May 11, 2022
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer
Jia-Tao Zhang, Si-Yang Liu, Wei Gao, et al.
Protein & Cell
|
November 27, 2023
Senktide blocks aberrant RTN3 interactome to retard memory decline and tau pathology in social isolated Alzheimer's disease mice
He-Zhou Huang, Wen-Qing Ai, Na Wei, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 28, 2017
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
Hai-Yan Tu, E-E Ke, Jin-Ji Yang, et al.
Page
of 95
Search research articles
Search
Showing results (921-930 of 948) with videos related to
Sort By:
Page
of 95
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 2017
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2019
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
Wen-Zhao Zhong, Ke-Neng Chen, Chun Chen, et al.
Cell Reports. Medicine
|
January 19, 2023
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study
Han-Min Wang, Chan-Yuan Zhang, Kai-Cheng Peng, et al.
Science Bulletin
|
January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial
Si-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
Signal Transduction and Targeted Therapy
|
December 6, 2023
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study
Si-Yang Liu, Song Dong, Xue-Ning Yang, et al.
Science Advances
|
April 21, 2023
Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease
Lan-Ting Zhou, Dan Liu, Hui-Cong Kang, et al.
Signal Transduction and Targeted Therapy
|
February 23, 2023
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, et al.
Cancer Discovery
|
May 11, 2022
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer
Jia-Tao Zhang, Si-Yang Liu, Wei Gao, et al.
Protein & Cell
|
November 27, 2023
Senktide blocks aberrant RTN3 interactome to retard memory decline and tau pathology in social isolated Alzheimer's disease mice
He-Zhou Huang, Wen-Qing Ai, Na Wei, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 28, 2017
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
Hai-Yan Tu, E-E Ke, Jin-Ji Yang, et al.
Page
of 95